Nuformix plc (LON:NFX – Get Free Report)’s stock price hit a new 52-week low on Thursday . The stock traded as low as GBX 0.16 ($0.00) and last traded at GBX 0.16 ($0.00), with a volume of 198199 shares trading hands. The stock had previously closed at GBX 0.17 ($0.00).
Nuformix Stock Performance
The company has a quick ratio of 3.35, a current ratio of 1.51 and a debt-to-equity ratio of 1.17. The business’s fifty day simple moving average is GBX 0.19 and its two-hundred day simple moving average is GBX 0.25. The company has a market cap of £1.39 million, a price-to-earnings ratio of -1.63 and a beta of 0.28.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Further Reading
- Five stocks we like better than Nuformix
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- MarketBeat Week in Review – 6/24 – 6/28
- Profitably Trade Stocks at 52-Week Highs
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
